Matchpoint Therapeutics closed a $150 million Series B to advance oral covalent small molecules for autoimmune and inflammatory diseases (ID: 68b514e3e4f784f1). The financing supports progression toward proof-of-concept activity in the company’s pipeline built around orally delivered chemistry. The round is part of a wider private-market push that also included Forbion’s record raise and other large venture rounds, signaling continued scale-up funding for platform-driven therapeutics (ID: 8a1ee1e7b9f8a4c0).